Since 2 years, we saw AI (Artificial Intelligence) spreading in more and more domains, sometime presented as the “panacée” of all problems. In healthcare, and especially in drug discovery, many announces are done but, to be honest, very few results are published. In the article, the author explains the advantages of using IA, in particular at the earliest steps of drug discovery. But, he also explains constraints and limits of these uses.

Even then, no drug is likely to come from AI alone. “What AI and machine learning promise to do is not magic,” Khalil explains. “It promises to help automate what we can learn from data, and I don’t think there is a pharma company out there that does not want that.”

Iya Khalil – Co-founder of GNS Healthcare

In HCC Pharma, we use AI to improve our pictures analyzing capacities. Our first results with machine learning are very promising and we are associated to a doctoral position that will be opened next September on this topic. If you are interested in this field, feel free to contact us!

Source: Adding Artificial Intelligence to Drug Discovery


Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

0 Comments

Leave a Reply